Sinovac Biotech, Ltd. Banner Image

Sinovac Biotech, Ltd.

  • Ticker SVA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Sinovac Biotech, Ltd. Logo Image
  • 501-1000 Employees
  • Based in Beijing, China
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac’s product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, Quadrivalent Influenza vaccine (“QIV”), H5N1 pandemic influenza (avianMore flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government’s vaccination campaign and stockpiling program.
4.8 / 5.0 (83)

Sinovac Biotech, Ltd. reports have an aggregate usefulness score of 4.8 based on 83 reviews.

Sinovac Biotech, Ltd.

Most Recent Annual Report

Sinovac Biotech, Ltd.
MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

Sinovac Biotech, Ltd. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!